Molecular Hydrogen Therapy Enhances Immune Markers in Treg, Plasma, Tr1 Cells, and KLRG1 Expression on Tc Cells: A Case of Acute SDH With Midline Shift and Uncal Herniation Post-decompressive Craniectomy.
Hui-Fu Hsu, Ruei-Yang Hu, Jeng-Wei Lu, Dueng-Yuan Hueng, Yi-Jung Ho, Shan-Wen Lui, Ting-Yu Hsieh, Kuang-Yih Wang, Hsiao-Chen Liu, Feng-Cheng Liu · In vivo (Athens, Greece) · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
The researchers administered hydrogen capsules as a novel adjunct therapy, beginning daily treatment immediately upon admission.
What the Researchers Studied
It may also protect mitochondria, support cell function, and regulate immune responses, making it a promising new treatment option for SDH.
How Molecular Hydrogen Was Used
The researchers administered hydrogen capsules as a novel adjunct therapy, beginning daily treatment immediately upon admission.
What the Researchers Found
The researchers administered hydrogen capsules as a novel adjunct therapy, beginning daily treatment immediately upon admission.
Authors’ Conclusion
The authors concluded that this case suggests that molecular hydrogen therapy may be a helpful adjunct treatment for SDH with midline shift.